Coupling of α1-adrenoceptors to ERK1/2 in the human prostate

Urologia Internationalis

Volumn 86, Issue 4, 2011, Pages 427-433

  Bauer, Ricarda M ^a   Strittmatter, Frank ^a   Gratzke, Christian ^a,d   Göttinger, Johanna ^a   Schlenker, Boris ^a   Reich, Oliver ^a   Stief, Christian G ^a   Hedlund, Petter ^b   Andersson, Karl Erik ^c   Hennenberg, Martin ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

1 Adrenoceptor blocker; 1 Adrenoceptor; Extracellular signal regulated kinase; Lower urinary tract symptoms; Prostate hyperplasia; Smooth muscle

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NORADRENALIN; PHENYLEPHRINE;

ARTICLE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; PRIORITY JOURNAL; PROSTATE; PROSTATECTOMY; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SMOOTH MUSCLE FIBER; STIMULATION; WESTERN BLOTTING;

ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; BUTADIENES; ENZYME INHIBITORS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MODELS, BIOLOGICAL; NITRILES; NOREPINEPHRINE; PHENYLEPHRINE; PHOSPHORYLATION; PROSTATE; RECEPTORS, ADRENERGIC, ALPHA-1; URINARY TRACT;

EID: 79959656492     PISSN: 00421138     EISSN: 14230399     Source Type: Journal    
DOI: 10.1159/000322639     Document Type: Article

References (30)

1. Roehrborn CG, Schwinn DA: Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. J Urol 2004;171:1029-1035. (Pubitemid 38327520)
2. Schwinn DA, Roehrborn CG: Alpha1-adre-noceptor subtypes and lower urinary tract symptoms. Int J Urol 2008;15:193-199. (Pubitemid 351316928)
3. Christ GJ, Andersson KE: Rho-kinase and effects of Rho-kinase inhibition on the lower urinary tract. Neurourol Urodyn 2007;26:948-954. (Pubitemid 47548232)
4. Xiao L, Pimental DR, Amin JK, Singh K, Sawyer DB, Colucci WS: MEK1/2-ERK1/2 mediates alpha1-adrenergic receptor-stimulated hypertrophy in adult rat ventricular myocytes. J Mol Cell Cardiol 2001;33:779-7871.
5. Zhang H, Chalothorn D, Jackson LF, Lee DC, Faber JE: Transactivation of epidermal growth factor receptor mediates catechol-amine-induced growth of vascular smooth muscle. Circ Res 2004;95:989-997. (Pubitemid 39532329)
6. Golomb E, Kruglikova A, Dvir D, Parnes N, Abramovici A: Induction of atypical prostatic hyperplasia in rats by sympathomimetic stimu lation. Prostate 1998;34:214-221. (Pubitemid 28156612)
7. Marinese D, Patel R, Walden PD: Mechanistic investigation of the adrenergic induction of ventral prostate hyperplasia in mice. Prostate 2003;54:230-237. (Pubitemid 36120321)
8. McVary KT, Razzaq A, Lee C, Venegas MF, Rademaker A, McKenna KE: Growth of the rat prostate gland is facilitated by the autonomic ner vous system. Biol Reprod 1994;51:99-107. (Pubitemid 24179226)
9. Kanagawa K, Sugimura K, Kuratsukuri K, Ikemoto S, Kishimoto T, Nakatani T: Norepinephrine activates P44 and P42 MAPK in human prostate stromal and smooth muscle cells but not in epithelial cells. Prostate 2003;56:313-318. (Pubitemid 36988752)
10. Chang L, Karin M: Mammalian MAP kinase signalling cascades. Nature 2001;410:37-401.
11. Michel MC, Vrydag W: Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol 2006;147(Suppl 2):S88-S119. (Pubitemid 43237577)
12. Luthin GR, Wang P, Zhou H, Dhanasekaran D, Ruggieri MR: Role of m1 receptor-G protein coupling in cell proliferation in the prostate. Life Sci 1997;60:963-968. (Pubitemid 27165563)
13. Maroni PD, Koul S, Meacham RB, Koul HK: Mitogen Activated Protein kinase signal transduction pathways in the prostate. Cell Commun Signal 2004;2:5.
14. McCubrey JA, Steelman LS, Chappell WH, et al: Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 2007;1773:1263-1284. (Pubitemid 47125967)
15. Royuela M, Arenas MI, Bethencourt FR, Sanchez-Chapado M, Fraile B, Paniagua R: Regulation of proliferation/apoptosis equilibrium by mitogen-activated protein kinases in normal, hyperplastic, and carcinomatous human prostate. Hum Pathol 2002;33:299-306. (Pubitemid 34461463)
16. Shimada K, Nakamura M, Ishida E, Konishi N: Molecular roles of MAP kinases and FADD phosphorylation in prostate cancer. Histol Histopathol 2006;21:415-422.
17. Srinivasan D, Kosaka AH, Daniels DV, Ford AP, Bhattacharya A: Pharmacological and functional characterization of bradykinin B2 receptor in human prostate. Eur J Pharmacol 2004;504:155-167. (Pubitemid 39488211)
18. Zhang Z, Duan L, Du X, et al: The proliferative effect of estradiol on human prostate stromal cells is mediated through activation of ERK. Prostate 2008;68:508-516. (Pubitemid 351500211)
19. Schilit S, Benzeroual KE: Silodosin: a selective alpha1A-adrenergic receptor antagonist for the treatment of benign prostatic hyperplasia. Clin Ther 2009;31:2489-2502.
20. Kyprianou N: Doxazosin and terazosin suppress prostate growth by inducing apoptosis: clinical significance. J Urol 2003;169:1520-15251.
21. Anglin IE, Glassman DT, Kyprianou N: Induction of prostate apoptosis by alpha1-ad-renoceptor antagonists: mechanistic significance of the quinazoline component. Prostate Cancer Prostatic Dis 2002;5:88-95. (Pubitemid 34777889)
22. Kyprianou N, Jacobs SC: Induction of apoptosis in the prostate by alpha1-adrenoceptor antagonists: a novel effect of 'old' drugs. Curr Urol Rep 2000;1:89-96.
23. Chon JK, Borkowski A, Partin AW, Isaacs JT, Jacobs SC, Kyprianou N: Alpha 1-adreno-ceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia. J Urol 1999;161:2002-20081.
24. Glassman DT, Chon JK, Borkowski A, Jacobs SC, Kyprianou N: Combined effect of terazosin and finasteride on apoptosis, cell proliferation, and transforming growth factor-beta expression in benign prostatic hyperplasia. Prostate 2001;46:45-51. (Pubitemid 32157775)
25. Turkeri LN, Ozyurek M, Ersev D and Akdas A: Apoptotic regression of prostatic tissue induced by short-term doxazosin treatment in benign prostatic hyperplasia. Arch Esp Urol 2001;54:191-196. (Pubitemid 32289566)
26. Erdogru T, Ciftcioglu MA, Emreoglu I, et al: Apoptotic and proliferative index after alpha-1-adrenoceptor antagonist and/or finasteride treatment in benign prostatic hyperplasia. Urol Int 2002;69:287-292. (Pubitemid 35365383)
27. Kyprianou N, Litvak JP, Borkowski A, Alexander R, Jacobs SC: Induction of prostate apoptosis by doxazosin in benign prostatic hy perplasia. J Urol 1998;159:1810-1815. (Pubitemid 29190702)
28. Roehrborn CG: Three months' treatment with the alpha1-blocker alfuzosin does not affect total or transition zone volume of the prostate. Prostate Cancer Prostatic Dis 2006;9:121-125. (Pubitemid 43970960)
29. Lucia MS, Lambert JR: Growth factors in benign prostatic hyperplasia: basic science implications. Curr Urol Rep 2008;9:272-278.
30. Royuela M, De Miguel MP, Bethencourt FR, Sanchez-Chapado M, Fraile B, Paniagua R: Transforming growth factor beta 1 and its receptor types I and II. Comparison in human normal prostate, benign prostatic hyperplasia, and prostatic carcinoma. Growth Factors 1998;16:101-110. (Pubitemid 29056119)